[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabete-type-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabete-type-2":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,49,87,115,146,173,200,222,247,266,288,311,341,368,390,412,441,466,494,519,555,577,615,638,661],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100636285","phase-1-safety-tolerability-and-efficacy-of-semaglutide-depot-in-subjects-with-type-2-diabetes-mellitus-100636285",false,"NCT07563699","Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus","A Prospective, Multicenter, Open Label, Dose Escalation Phase I\u002FIIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus","Inclusion Criteria:\n\n1. Adults aged 18-64 years with T2DM, BMI 25-35 kg\u002Fm2\n2. On stable Semaglutide 1 mg weekly and for at least 3 months\n3. HbA1c \\\u003C8%, eGFR≥60 ml\u002Fminute\n4. For women: either non-childbearing potential or agreement to use acceptable contraception\n\nExclusion Criteria:\n\n1. Participation in another investigational drug clinical study within 3 months\n2. History of cardiovascular or cerebrovascular disease\n3. Neuropathy or retinopathy or macular edema necessitating medical treatment\n4. Type 1 diabetes\n5. Unstable weight (\\> 5% change in the last 3 months)\n6. Current use of insulin and \u002For sulfonylureas and\u002For glinides\n7. Known contraindications to Semaglutide (per FDA-approved Semaglutide label)\n8. Recent immunosuppressive therapy (within 90 days) or chemotherapy for malignancy within 5 years\n9. Moderate or severe hepatic impairment, (ALT or AST\\> 2 x upper limit of normal (ULN)\n10. Severe hypertriglyceridemia (triglycerides \\>500 mg\u002Fdl)\n11. Pregnant or breast feeding\n12. Any condition that may increase risk or interfere with study participation (per Investigator judgement)","ALL","18 Years","64 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction. Semaglutide Depot, is a long-acting formulation of semaglutide, designed for once every four weeks administration, intended to reduce treatment burden, and improve adherence supporting sustained glycemic control over time.\n\nThis Phase I\u002FIla dose escalation study design to evaluate the safety, tolerability, pharmacokinetics and efficacy of Semaglutide Depot in adults with T2DM.",[29],"Diabete Type 2",[31,32,33,34,35],"Diabetes","Semaglutide Depot","Long-acting semaglutide","SG Depot","semaglutide LAI","NOT_YET_RECRUITING","2026-06-28",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":22},"2026-07",{"date":44,"type":22},"2028-05",{"name":46,"class":47},"Mapi Pharma Ltd.","INDUSTRY",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100644908","peel-family-diabetes-prevention-program-100644908","NCT07675551","Peel Family Diabetes Prevention Program","Peel Family Diabetes Prevention Program (Peel FDPP): Family-Centred Health and Wellness Coaching Pilot Randomized Controlled Trial","Peel FDPP","Inclusion Criteria:\n\nDyad participants will consist of a self-identified primary family caregiver aged 18 years or older and a youth family member aged 14 to 24 years at the time of study entry. The primary family caregiver will serve as the primary (index) research participant for the dyad and should have the following inclusion criteria:\n\n1. Self-identifies as either South Asian or Black, African and Caribbean.\n2. Lives in the Peel Region (Mississauga, Brampton or Caledon), Ontario, Canada.\n3. Be 18 years or older and have a youth child aged 14 to 24 years in the household who is willing and consents to participate. AND\n4. Have no medical diagnosis (self-reported) of diabetes.\n5. Have no medical diagnosis (self-reported) of prediabetes that requires any medical or pharmacological treatment.\n\n   Have a blood-based sugar greater than or equal to 6.5 measured through the hemoglobin A1c test using a finger prick at the pre-enrollment assessment visit. AND\n6. The family dyad (family caregiver and youth) must be proficient in English (reading, writing, and speaking), as English will be the primary language used for the participation eligibility, implementation, delivery, and evaluation of the intervention.\n\nExclusion Criteria for family dyad:\n\n1. Do not meet all the criteria above.\n2. A medical condition or health professional has advised them not to engage in physical activity of any type, or they are following a specific diet.\n3. Cannot give informed consent to participate voluntarily in the intervention and study.",true,"14 Years",{"count":60,"type":22},280,[62],"NA","The goal of this Hybrid Type 2 effectiveness-implementation pilot randomized controlled trial is to assess the feasibility and preliminary effectiveness of a community-based wellness coaching intervention to prevent type 2 diabetes (T2D) among South Asian (SA) and Black African and Caribbean (BAC) communities in the Peel region of Ontario, Canada. The study evaluates the impact of the intervention on reducing diabetes risk and related intermediate outcomes, including biomarkers, anthropometric measures, well-being, knowledge, health behaviours, and family-level outcomes in participating family dyads.\n\nEach SA and BAC family dyad will consist of a primary adult family caregiver aged 18 years or older, who does not have T2D and is not taking pharmacological treatment for blood glucose reduction, and a youth aged 14 to 24 years residing in the same household. The study aims to generate preliminary evidence on both the implementation and effectiveness of the intervention over a 12-month period.\n\nParticipant dyads of each ethnocultural group (SA and BAC) will be randomly assigned to either the intervention or control arm. During the first six months, participants in the intervention arm will receive biweekly health and wellness coaching delivered by trained community-based coaches, optional group coaching sessions with other participants, weekly motivational messages, and an educational T2D prevention booklet. Participants in the control arm will receive only the educational T2D prevention booklet.\n\nImplementation and effectiveness outcomes will be assessed using a mixed-methods approach, integrating qualitative and quantitative data collected at baseline and at the 6- and 12-month post-randomization time points. This approach is intended to generate comprehensive, preliminary evidence on both the implementation and effectiveness components of the health and wellness intervention. Quantitative and mixed-methods analyses will be conducted to provide an integrated understanding of the implementation and effectiveness outcomes studied.\n\nFindings from this pilot trial will inform the design of larger, definitive studies to better assess impact and guide future escalation and\u002For adaptation.\n\nResults will be disseminated in multiple formats and tailored to diverse audiences, including community partners, local communities, academics, researchers, and decision-makers.",[29],[66,31,67,68,69,70,71,72,73,74,75],"Diabetes Risk","Coaching","Intervention","Implementation","Effectiveness","Family","Diet Habits","Physical Activity","Mental Well-being","Health Behaviors","RECRUITING","2026-06-26",{"date":39,"type":40},{"date":80,"type":40},"2026-05-20",{"date":82,"type":22},"2028-03-31",{"name":84,"class":85},"Trillium Health Partners","OTHER",2,{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100644833","evaluate-the-effect-of-remote-exercise-intervention-on-blood-glucose-control-and-physical-fitness-in-t2dm-patients-100644833","NCT07676773","Evaluate the Effect of Remote Exercise Intervention on Blood Glucose Control and Physical Fitness in T2DM Patients","A 12 Weeks Clinical Trail to Evaluate the Effect of Remote Exercise Intervention on Blood Glucose Control and Physical Fitness in T2DM Patients","Inclusion Criteria:\n\n(1) Both gender, age from 40 to 69 years old. (2) Meeting the diagnostic criteria for type 2 diabetes in China. (3) HbA1c is within 6.5%-7 .0% and no medication is taken. (4) Newly diagnosed with diabetes or the duration of the disease is no more than 5 years. (5) Possessing general exercise capacity and no obvious diseases in the muscle and osteoarticular systems. (6) The exercise risk is evaluated as medium or low risk through the PAR-Q+ questionnaire. (7) No contraindications to exercise tests. (8) Willing to adopt intensifed lifestyle intervention and complete the entire research process.\n\nExclusion Criteria:\n\n(1) T1DM patients, autoimmune diabetes and special types of diabetes, including hypercortisolism, growth hormone tumor, glucagonoma and some special types of diabetes caused by genetic factors; (2) pregnant or lactating women; (3) regular use of antidiabetic drugs or insulin in the past three months; (4) fasting blood glucose level \\> 16.7 mmol\u002FL; (5) recurrent hypoglycemia; (6) a history of acute diabetic complications, including diabetic ketoacidosis, hyperosmolar hyperglycemia, and lactic acidosis; (7) a history of severe chronic microvascular or macrovascular complications; (8) diseases that may be exacerbated by exercise or impair exercise efciency, such as uncontrolled hypertension, hyperthyroidism, osteoarthritis or hypokalemia; (9) unable to use smart phones or wearable smart devices independently; (10) communication or motor dysfunction; (11) Patients with severe chronic diseases could not participate in the study.","69 Years",{"count":96,"type":22},80,[62],"The intervention group received 12 weeks of continuous remote intervention combined with health education. The control group only received 12 weeks of continuous health education, and the content and frequency were the same as those of the management group. Both groups received instruction at the beginning of the intervention. The intervention group was given priority to continuous walking\u002Frunning combined with aerobic exercise and swimming. Five to seven sessions per week for 45 minutes each session. Acclimatizations were performed at an intensity of 40%-49% reserve oxygen uptake (VO2R) from weeks 1 to 4, and exercise was performed at an intensity of 50%-59% VO2R from weeks 5 to 12. 5 minutes each of preparation and grooming activities (including joint movement and stretching) for each exercise. Combined with incremental load resistance exercise 2-3 times a week, 8 movements, 2-3 groups each time, repeated 8-10 times\u002Fgroup, with a 2-min rest between groups. The heart rate, RPE (12-13, \"fairly easy\" to \"somewhat laborious\") and exercise bracelet were used to monitor the intensity and amount of exercise. The exercise intervention was usually delivered 1-2 h after a meal. The daily medical supervision in the process of management implementation was carried out by trained sports managers through the doctor terminal of \"exercise assistant\" to collect and monitor the data of the study subjects.",[29,100],"Cardio Respiratory Fitness",[102,103,104,105,106],"Type 2 diabetes mellitus","Integration of sports and healthcare","Randomized controlled trial","Exercise prescription","Remote exercise intervention","2026-06-24",{"date":39,"type":40},{"date":110,"type":40},"2026-06-01",{"date":112,"type":22},"2026-12-31",{"name":114,"class":85},"Sichuan Academy of Medical Sciences",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100640071","feasibility-of-a-person-centered-nursing-intervention-on-adherence-and-control-in-patients-with-arterial-hypertension-and-diabetes-mellitus-100640071","NCT07619677","Feasibility of a Person-centered Nursing Intervention on Adherence and Control in Patients With Arterial Hypertension and Diabetes Mellitus.","Feasibility of a Person-centered Nursing Intervention on Adherence and Control in Patients With Arterial Hypertension and Diabetes Mellitus. CERCANO Pilot Trial.","CERCANO pilot","Inclusion Criteria:\n\n1. Adults (18 years or older).\n2. Diagnosis of type 2 diabetes mellitus (DM) or arterial hypertension (HTN) (or both), documented in the medical record.\n3. Prescription of pharmacological treatment for the condition.\n4. Enrollment in a cardiovascular or metabolic risk program and scheduled for a medical follow-up visit within the next 3 to 6 months.\n\nExclusion Criteria:\n\n* Mental disorders that impair autonomy or understanding of the interventions.\n* Congestive heart failure, ischemic or valvular heart disease, end-stage renal disease requiring dialysis, chemotherapy treatment, autoimmune diseases, recent hospitalization due to disease decompensation (within the last month), or any other condition preventing the patient from receiving general health recommendations according to their primary diagnosis.\n* Physical limitations such as quadriplegia, total loss of motor function, or contraindications to physical activity as indicated by medical prescription.",{"count":124,"type":22},100,[62],"Background. Approximately 80% of people with type 2 diabetes mellitus (DM) or arterial hypertension (HTN) do not achieve adequate disease control.\n\nObjective. To evaluate the feasibility of a research study assessing the impact of an educational and nursing counseling intervention with a person-centered care (PCC) approach to improve adherence and control in patients with arterial hypertension and diabetes mellitus in Colombia.\n\nMethods. A pilot randomized controlled clinical trial will be conducted. Adults with DM or HTN enrolled in cardiovascular or metabolic risk programs will be included. A total of 100-200 patients is expected to be recruited. The intervention group will receive counseling and education tailored to their preferences following the PCC approach, while the control group will receive standard care according to the program they belong to. Follow-up will last 6 months, and the primary outcomes to be measured in both groups are: medication adherence, DM control (HbA1c at target levels, change in HbA1c), and HTN control (SBP and DBP at target levels, changes in SBP and DBP).\n\nResults. The findings of this study will provide insight into the feasibility of conducting larger-scale studies to evaluate the effectiveness of PCC-based interventions in Colombia.",[29,128,129],"Diabetes Education","Hypertension Arterial",[131,132,133,134,135,136,137],"Person-centered care","Hypertension","Diabetes type 2","Control","Adherence","Nursing interventions","Education",{"date":139,"type":40},"2026-06-04",{"date":141,"type":22},"2026-06",{"date":143,"type":22},"2027-03",{"name":145,"class":85},"Universidad Autónoma de Bucaramanga",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":48},"100621596","pocket-x-gel-non-surgical-periodontal-therapy-100621596","NCT07372677","Pocket-X Gel Non-surgical Periodontal Therapy","Clinical and Microbiological Effects of a Thermal-Gel Device in Periodontal Treatment: Diabetic vs Non-Diabetic Patients","DEFECT_PERIO","Inclusion Criteria:\n\nPatients normally eligible for the visit and for the non-surgical type of treatment for periodontal defects:\n\n* patients with an age between 18 and 80;\n* patients with: (i) Asa status I (no functional impairment due to pathologies), (ii) patients with type 2 diabetes (T2DM) with: glycated hemoglobin level HbA1c between 6.5 and 8.0%, on dietary therapy and\u002For with hypoglycemic drugs in regular follow-up at the diabetes service;\n* patients with chronic periodontitis stage 3 or 4, according to the new classification of periodontal diseases \\[Tonetti et al.\\]), verified clinically and radiographically: patients will be selected with interdental clinical attachment level (CAL) at the site of greatest loss ≥3 mm to ≥2 non-adjacent teeth, probing depth (PPD) ≥5 mm, bleeding on probing (BoP) and horizontal and\u002For vertical radiographic bone loss.\n\nExclusion Criteria:\n\n* Patients not eligible for the non-surgical type of treatment for periodontal defects:\n\n  * patients with a positive history of diseases with functional impairment (ASA status 2,3,4) or severe handicaps that could limit the ability to attend appointments;\n  * patients with uncontrolled\u002Fpoorly controlled DM at the time of study selection (e.g. type 1 diabetes mellitus and secondary forms of diabetes); patients with uncontrolled and serious diabetic complications (cardiovascular, renal, hepatic and nervous);\n  * poor compliance with treatment, with poor oral hygiene and motivation;\n  * not signing informed consent by patients.","80 Years",{"count":156,"type":22},70,[62],"Evaluate from a clinical and microbiological point of view the effect of an adjunctive therapy based on a thermal-gelling device Pocket-X® Gel (Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL, Water), in the non-surgical treatment of periodontal defects, in a population of patients with T2DM compared to non-diabetic patients.\n\nDetermine whether periodontal defect healing is clinically and microbiologically different between T2DM patients and non-diabetic patients; whether periodontal treatment and maintenance can lead to improvement of conditions and stability over time also for diabetic conditions.",[29],[161,162,163],"Non-surgical periodontal therapy","Pocket-X gel","periodontitis in diabetes type-2","2026-05-28",{"date":166,"type":40},"2026-05-29",{"date":168,"type":40},"2026-02-02",{"date":170,"type":22},"2030-01",{"name":172,"class":85},"Universita di Verona",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":48},"100635183","effect-of-diode-laser-gudmar-and-vinegar-in-diabetic-patients-during-root-canal-treatment-100635183","NCT07549373","Effect of Diode Laser, Gudmar and Vinegar in Diabetic Patients During Root Canal Treatment","Antibacterial Effect Of 940nm Diode Laser, Apple Cider Vinegar And Gymnema Sylvestre In Diabetic Patients With Apical Periodontitis Against Peptostreptococcus Species- A Randomized Clinical Trial","Inclusion Criteria:\n\n* Using radiographs, intraoral periapical radiographs (RVG) primary endodontic infection will be selected.\n* Multirooted teeth , root with periapical lesion will be selected\n* Type 2 diabetics between the ages of 25 years and 60 years will be chosen; both male and female patients\n* A fasting blood sugar level of 126 mg\u002Fdl and a random blood sugar level of less than 200 mg\u002Fdl\n* HbA1c (glycated haemoglobin) ≥ 6.5%\n\nExclusion Criteria:\n\n* Patients with systemic conditions other than type 2 diabetes\n* Women who are pregnant\n* Those patients that have used antibiotics within the previous three months,\n* Those patients that have teeth with developmental defects, calcified canals,\n* Teeth that cannot be isolated with rubber dams,\n* Tortuous canals\n* Roots that are fractured","25 Years","60 Years",{"count":183,"type":22},90,[62],"Methodology\n\nPatient with diabetes 2 with informed consent -convenience sampling over a one year period.The tooth isolated with a rubber dam and the correct disinfection procedures will be used. researcher will do the Access preparation Working length -electronic apex locator (Dentsply Propex II) as well as a radiographic approach.\n\nAfter the canals will be obturated using ZOE sealer and gutta percha and post endodontic restoration is done using composite restoration. Patient is kept on follow up for 7days, 15 days, 30 days ,45 days and 60 days Clinical outcome is measure using periapical radiograph (RVG) Pain is measured using visual analog scale to mark the pain intensity. Data will be analysed statistically To enlarge the root canals (ISO size 20 file)\n\nA sterile paper point inside the root canal for one minute until the apex of the root canal is reached\n\nUsing T.E Buffer, samples will be delivered to the School Of Basic Life Sciences, Sharda University.\n\nThe samples will be subjected to traditional PCR analysis for the detection of Peptostreptococcus spp. in the root canal.\n\nGrouping Following instrumentation, 5% NaOCl and 17% EDTA irrigation will be done. Control group (n=15) The final irrigant will be saline Group 1 (n=15) Irrigation using 5% apple cider vinegar done The final irrigant will be saline Group 2 (n=15) Diode laser is used for disinfection in the presence of saline Group 3 (n=15) Gymnema Sylvestre Mother Tincture Q 1000 CH solution is used for disinfection in the presence of saline Group 4 (n=15) Diode laser is used for disinfection in the presence of 5% apple cider vinegar. The final irrigant will be saline Group 5 (n=15) Diode laser is used for disinfection in the presence of Gymnema Sylvestre Mother Tincture Q 1000 CH solution. The final irrigant will be saline\n\nAfter cleaning and shaping, samples will be collected and sent through T.E. Buffer to the School Of Basic Life Sciences, Sharda University.\n\nThe samples will be subjected to traditional PCR analysis for the detection of Peptostreptococcus spp. in the root canal.",[29],[188,189,190,191],"Endodontics","Diode laser","Apple cider vinegar","Gymnema sylvestre","2026-05-24",{"date":164,"type":40},{"date":195,"type":22},"2026-05-01",{"date":197,"type":22},"2027-05-01",{"name":199,"class":85},"Sharda University",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":57,"sex":17,"minAge":207,"maxAge":19,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100639668","phase-1-a-study-to-compare-the-pharmacokinetics-and-safety-of-the-atb-u101-and-atb-u1011atb-u1012-and-atb-1011atb-1012-in-healthy-caucasian-participants-100639668","NCT07590466","A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants","A Phase 1, Open-Label, Randomized, Crossover, Single-dose Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants","Inclusion Criteria:\n\n* Healthy Caucasian adult volunteers aged between 19 and 64 years (inclusive) at the time of screening\n* Caucasian volunteers: Individuals whose parents and grandparents are European, North American, or Middle Eastern, who were born in Europe, North America, or Western Asia, and whose cumulative residence in countries outside those regions since birth is less than 10 years\n* Individuals whose weight at screening is between 50.0 kg and 97.0 kg and whose body mass index (BMI) is between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2\n\nExclusion Criteria:\n\n* Subjects with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n* Subjects who test positive on serologic tests (hepatitis B, hepatitis C, human immunodeficiency virus \\[HIV\\], or syphilis)","19 Years",{"count":209,"type":22},36,[25],"The goal of this Phase 1 clinical trial is to compare the pharmacokinetics and safety of a fixed-dose combination tablet (ATB-U101) versus co-administration of its individual components in healthy Caucasian adult volunteers. The main questions it aims to answer are:\n\n* Is the Cmax of Olmesartan and Dapagliflozin bioequivalent across the three treatment regimens?\n* Is the AUClast of Olmesartan and Dapagliflozin bioequivalent across the three treatment regimens?\n\nResearchers will compare ATB-U101 (fixed-dose combination, 40 mg\u002F10 mg) against two reference co-administrations - ATB-1011+ATB-1012 (Korean-approved Olmetec + Forxiga) and ATB-U1011+ATB-U1012 (US-approved Benicar + Farxiga) - to see if the 90% confidence intervals of the geometric mean ratios for the primary PK parameters fall within the bioequivalence range of 80.00-125.00%.\n\nParticipants will:\n\n* Be admitted to the clinical trial center three times (Days 1, 8, and 15), each separated by a 7-day washout period\n* Receive a single oral dose of one assigned treatment per period under fasting conditions (minimum 10 hours) with 240 mL of water, in a randomized crossover sequence\n* Have blood samples collected at up to 18 timepoints per period (up to 48 hours post-dose) for PK analysis\n* Undergo safety assessments including vital signs, ECG, physical examination, and laboratory tests throughout the study, with a final follow-up visit around Day 21-24",[29,132],"2026-05-12",{"date":215,"type":40},"2026-05-15",{"date":217,"type":22},"2026-05-18",{"date":219,"type":22},"2026-08-31",{"name":221,"class":47},"Autotelicbio",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":48},"100624906","artichoke-by-products-rich-in-hydroxycinnamic-acids-and-mediterranean-diet-for-type-2-diabetes-prevention-100624906","NCT07415720","Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.","Multiomic Evaluation of the Effect of Artichoke By-products Supplementation Rich in Hydroxycinnamic Acids, Integrated Into an Energy-restricted Mediterranean Diet, on the Prevention of Type 2 Diabetes.","ARTI-UP","Inclusion Criteria:\n\n* BMI between 25.0 and 35.0 kg\u002Fm²\n* HOMA-IR ≥ 2.5.\n* Adequate physical examination and vital signs or clinically irrelevant to the intervention (those not related to metabolic health).\n* Subjects must be able to understand and be willing to sign the informed consent form, and must comply with all study procedures and requirements.\n* Subjects must have a stable means of communication, either by email and\u002For telephone.\n\nExclusion Criteria:\n\n* Weight loss of more than 5% in the last 6 months prior to surgery.\n* Consumption of antibiotics in the 3 months prior to the intervention.\n* Subjects who are undergoing treatment for weight loss\u002Fbody composition modification, use medication for weight loss or blood glucose control, or have had weight loss surgery.\n* Have a medical diagnosis of type 1 or type 2 diabetes.\n* History of inflammatory bowel disease and\u002For resection of the large or small intestine. Subjects with relevant functional or structural abnormalities of the digestive system.\n* Inability to follow the recommended diet or physical exercise.\n* Unavailability in terms of time or location to attend study visits.\n* Failure to sign the informed consent form.\n* Inability to communicate with the research team.\n* Endocrine-related excess weight (except for treated hypothyroidism, at least 3 months of stable treatment).\n* Being pregnant or planning a pregnancy during the intervention period.\n* Being breastfeeding.\n* Having an allergy to artichokes.\n* Severe psychiatric illnesses that have required hospitalisation in the last 6 months.\n* Renal failure.\n* Having immunodeficiency or being HIV positive.\n* Being treated with immunosuppressive drugs or cytotoxic agents.\n* High alcohol intake: more than 14 units (women) and 20 units (men) per week.\n* Participation in another randomised clinical trial.\n* Volunteers undergoing drug treatment for less than 3 months with a stable dose\u002Fstable treatment.\n* Taking nutritional supplements (supplements: plant derivatives, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for 3 months prior to the start of the trial.\n* Taking nutritional supplements (supplements: plant-derived, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for the 16 weeks of the study intervention and a minimum washout period of 14 days prior to baseline measurements is guaranteed.\n* Having donated blood in the 14 days prior to the baseline visit.\n* Subjects with any type of cancer or undergoing treatment for cancer, or who have not been in remission for at least 5 years.\n* Any other condition that may interfere with adherence to the intervention.","75 Years",{"count":232,"type":22},150,[62],"The ARTI-UP study evaluates whether daily consumption of a supplement made from artichoke by-products, rich in hydroxycinnamic acids (HCAs), in combination with an energy-restricted Mediterranean diet (erMeDiet), can improve glycaemic control, reduce insulin resistance and contribute to weight loss in subjects with overweight or obesity. In addition, it seeks to understand the biological mechanisms involved using omic techniques and to establish predictive biomarkers that will enable progress towards personalised nutrition strategies.",[29,236,237],"Obesity & Overweight","Insulin Resistance Syndrome","2026-04-28",{"date":240,"type":40},"2026-04-29",{"date":242,"type":22},"2026-05",{"date":244,"type":22},"2027-12",{"name":246,"class":85},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":253,"targetDuration":254,"studyType":255,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":264,"locationsCount":48},"100635731","role-of-endothelial-progenitor-cells-dysregulation-and-inflammation-in-the-pathophysiology-of-cardiovascular-complications-of-type-2-diabetes-100635731","NCT07556497","Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes","Inclusion Criteria:\n\n* T2D\n* Males and females\n* Older than 18 years of age\n* Willingness to participate in the study and provide written consent form\n* Consent to having peripheral blood withdrawals and urine collection for the study requirement.\n\nExclusion Criteria:\n\n* Unable to meet the inclusion criteria\n* Type I diabetes, MODY diabetes or other form of diabetes\n* Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).\n* Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).\n* Evidence of malignancy within the past 5 years",{"count":183,"type":22},"6 Months","OBSERVATIONAL","This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.",[29,258],"Cardio Vascular Disease","2026-04-21",{"date":240,"type":40},{"date":262,"type":40},"2020-11-17",{"date":112,"type":22},{"name":265,"class":85},"Weill Cornell Medical College in Qatar",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":207,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":48},"100635415","phase-3-clinical-trial-to-evaluate-the-efficacy-and-safety-of-monotherapy-group-of-hl1113r1-or-hl1113r2-versus-hl1113-fixed-dose-combination-in-patients-with-essential-hypertension-and-type-ii-diabetes-mellitus-100635415","NCT07552389","Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus","A Randomized, Active Controlled, Double Blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus","Inclusion Criteria:\n\n* Adult male or female subjects aged ≥19 years at the time of written informed consent.\n* Subjects diagnosed with essential hypertension accompanied by type 2 diabetes mellitus.\n* etc.\n\nExclusion Criteria:\n\n* Subjects whose blood pressure measured in the selected arm at both screening and randomization meets the following criterion: MSDBP ≥ 110 mmHg\n* Subjects whose blood pressure measured three consecutive times in each arm at intervals of at least 2 minutes at screening shows a difference of ≥20 mmHg in SBP and ≥10 mmHg in DBP.\n* etc.",{"count":274,"type":22},228,[276],"PHASE3","This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus",[132,29],"2026-04-20",{"date":281,"type":40},"2026-04-27",{"date":283,"type":40},"2025-12-18",{"date":285,"type":22},"2028-12",{"name":287,"class":47},"Hanlim Pharm. Co., Ltd.",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100633569","comorbidity-oriented-primary-care-and-integrated-management-for-hypertension-and-diabetes-mellitus-100633569","NCT07528391","Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus","Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus: A Cluster Randomised Controlled Trial in Rural China","COMPACT-HTDM","Inclusion Criteria:\n\nCluster level (primary care facilities):\n\n* Township health centers or community health service centers that provide routine primary care management services for both hypertension and diabetes.\n* Agree to participate in cluster randomization and study procedures.\n* Have basic capacity for chronic disease follow-up and data recording.\n\nIndividual participant level (patients):\n\n* Aged 60 to 74 years.\n* Diagnosed with hypertension and type 2 diabetes mellitus for at least 6 months.\n* Received at least one chronic disease management service at the participating study site within the past 6 months.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\nCluster Level (Primary Care Facilities):\n\n* Facilities currently participating in other intervention studies or pilot programs targeting hypertension and\u002For diabetes management that may interfere with the study intervention.\n* Facilities with major organizational instability (e.g., restructuring, closure, or significant staff turnover) that would affect implementation or follow-up.\n\nIndividual Level:\n\n* Severe cognitive impairment or psychiatric illness affecting participation or follow-up.\n* Anticipated inability to complete 6-month follow-up.","74 Years",{"count":298,"type":22},960,[62],"The COMPACT-HTDM study is a parallel, two-arm cluster randomized controlled trial designed to evaluate a comorbidity-oriented integrated primary care management model for elderly patients with coexisting hypertension and type 2 diabetes mellitus in community health centers and township health centers. The trial aims to determine whether an integrated comorbidity management package can improve metabolic control and cardiovascular risk management compared with usual disease-specific care in routine primary care settings. Clusters are primary care facilities randomized 1:1 to intervention or control by an independent statistician using a computer-generated random sequence. Patients aged 60-74 years with diagnosed hypertension and type 2 diabetes for at least six months and recent use of chronic disease management services at the study site will be recruited through chronic disease registries. The intervention includes comorbidity-focused medication optimization and safety management, integrated lifestyle management, self-management and community support, training for primary care staff, standardized toolkits and workflow embedding, an integrated comorbidity management platform, and feedback\u002Fincentive mechanisms. The control group will continue current standard primary care management for hypertension and diabetes under existing national guidelines. Participants will be followed for six months, with possible extension to 12 months for longer-term outcomes. The primary outcome is the proportion of participants achieving both blood pressure and glycemic control targets, defined as SBP\u002FDBP \\\u003C130\u002F80 mmHg and HbA1c \\\u003C7.0%. Secondary outcomes include BMI, blood lipids, medication adherence, lifestyle behaviors, follow-up completion, referral rate, and safety events such as hypoglycemia and hypotension; implementation outcomes include acceptability, fidelity, and feasibility.",[132,29,302],"Comorbidities and Coexisting Conditions","2026-04-07",{"date":305,"type":40},"2026-04-14",{"date":195,"type":22},{"date":308,"type":22},"2028-12-31",{"name":310,"class":85},"Nanchang University",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":48},"100632779","phase-1-a-bridging-study-of-efsubaglutide-alfa-in-healthy-adults-in-brazil-100632779","NCT07518121","A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil","A Randomized, Double-Blind, Placebo-Controlled Bridging Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Efsubaglutide Alfa in Healthy Adult Participants in Brazil","BRIDGE-BR","Inclusion Criteria:\n\n1. Healthy male or female adults, aged 18-45 years (both inclusive) at the time of signing the informed consent form (ICF).\n2. Body mass index (BMI) between 18-28 kg\u002Fm2 (both inclusive). Male participants must weigh no less than 50 kg, and female participants must weigh no less than 45 kg.\n3. Voluntary participation in this study, as documented by the written signature of two copies of the ICF.\n4. Negative serum pregnancy test for women of childbearing potential (WOCBP) during screening period. WOCBP and fertile male participants with WOCBP partners must use highly effective contraception methods without planning to become pregnant or to donate sperm or eggs throughout this study (from signing the ICF to at least 3 months after completion of this study).\n5. Be able to maintain good communication with the investigators and comply with all requirements of protocol to complete all trial procedures.\n\nExclusion Criteria:\n\n1. Known or suspected allergy to the investigational medicinal product, its components or drugs of the same class, or a clinically significant drug allergy, or a history of atopic allergic disease.\n2. Previously or currently diagnosed diabetes mellitus (T1D or T2D) or prediabetes, according to the diagnostic criteria of the Brazilian Diabetes Society (SBD) guideline, defined by any of the following laboratory findings:\n\n   * FPG ≥126 mg\u002FdL or ≥7.0 mmol\u002FL ;\n   * FPG 100-125 mg\u002FdL or 5.6 -6.9 mmol\u002FL (prediabetes);\n   * HbA1c ≥ 6.5% or ≥48 mmol\u002Fmol;\n   * HbA1c 5.7-6.4% or 39-47 mmol\u002Fmol (prediabetes).\n3. History of clinically significant endocrine disorders that may affect glucose metabolism, body weight, or drug PK, including but not limited to Cushing's syndrome; acromegaly; pheochromocytoma; untreated or uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism); polycystic ovary syndrome (PCOS) with metabolic abnormalities; adrenal insufficiency or other adrenal disorders; pituitary disorders affecting hormonal regulation.\n4. History of acute or chronic pancreatitis, symptomatic gallbladder disease (those who have recovered from cholecystectomy and have no sequelae after treatment are allowable to be enrolled), pancreatic injury or other high-risk factors that may lead to pancreatitis, or screening serum amylase or lipase \\>2X upper limit of normal (ULN).\n5. History of significant gastrointestinal (GI) disorders (e.g., gastroparesis, active ulcers within 6 months, or long-term use of medications that directly affect GI motility, or GI surgery within 6 months prior to screening.\n6. History or presence of hepatic, renal, cardiovascular, neurological, psychiatric, psychological or immunological disorders.\n7. Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or 12-lead ECG at screening, and investigators consider that these abnormalities may affect participant's safety or study results. ECG abnormalities including but not limited to: second- or third-degree atrioventricular block; long QT syndrome or QTcF \\> 450 ms (males) or \\> 470 ms (females). (If the QTcF \\> 450 ms (males) or \\> 470 ms (females), two additional ECG measurements should be repeated, and the mean of the three values should be used to determine the participant's eligibility.); left bundle branch block;Wolff-Parkinson-White syndrome; Or other clinically significant 12-lead ECG abnormalities requiring treatment.\n8. Use of any prescription or over-the-counter (OTC) medications, traditional Chinese medicine within 12 months prior to screening that may confound PK, PD, or safety assessments.\n9. Personal or family history of thyroid C-cell tumors including medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia type 2 (MEN2), or presence of hyperthyroidism or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for at least 3 months or longer).\n10. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBSAg) and HBV-deoxyribonucleric adic (DNA) ≥ lab-specific ULN (for those with positive result on HBsAg, HBV-DNA test will be performed), hepatitis C antibody (HCV-Ab) and HCV-ribonucleric acid (RNA), participant can be eligible at the discretion of the investigator if HCV-Ab positive and HCV RNA negative, or Treponema pallidum antibody (TP-Ab).\n11. Pregnant or breastfeeding women.\n12. Donation or loss of ≥400 mL of blood within 3 months prior to screening.\n13. History of drug abuse within 1 year prior to screening, or positive drug abuse screening test (including amphetamines (AMP), cocaine (COC), tetrahydrocannabinol (THC), morphine (MOP), benzodiazepines (BZO), and methamphetamines (MET), any one or more of which tested positive).\n14. Consumption of more than 14 units of alcohol per week within 6 months prior to screening (1 unit of alcohol equivalent to 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine), or consumption of alcohol-containing products within 48 hours before administration, or positive breath alcohol test before administration.\n15. Participation in other clinical trials of vaccines, medical devices, or other drugs within 12 months prior to screening\n16. Major surgery within 4 weeks prior to screening, or planned major surgery during the study.\n17. Participant with systolic blood pressure (SBP) \\\u003C 90 mmHg or \\> 140 mmHg, or diastolic blood pressure (DBP) \\\u003C 50 mmHg or \\> 90 mmHg after resting in a sitting position, or heart rate (HR) \\\u003C 50 beats per minute (BPM) or \\> 100 bpm at rest in sitting position at the screening.\n18. Any other factors that may affect participation in this study at the discretion of the investigator.","45 Years",{"count":321,"type":22},48,[25],"This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011. Participants will be randomized to receive a single subcutaneous dose of YN-011 1 mg, YN-011 3 mg, or matching placebo. The study includes screening, approximately 2 days of study-site confinement from the day before dosing to 24 hours after dosing, and outpatient follow-up for 4 weeks. Assessments include safety monitoring, PK blood sampling, PD evaluations, and immunogenicity testing.",[29],[326,327,328,329,330,331,332],"Efsubaglutide Alfa","Phase 1","Healthy Volunteers","Pharmacokinetics","Brazil","Bridging Study","GLP-1 Receptor Agonist","2026-04-01",{"date":335,"type":40},"2026-04-08",{"date":110,"type":22},{"date":338,"type":22},"2026-10-31",{"name":340,"class":85},"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":351,"studyType":255,"phases":4,"briefSummary":352,"conditions":353,"keywords":356,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":366,"locationsCount":48},"100631874","investigation-of-gastric-emptying-by-gastric-ultrasonography-in-diabetic-patients-treated-with-glp-1-receptors-100631874","NCT07506356","Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors","Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists","SAGUSE","Inclusion Criteria:\n\n* Female\u002F Male of 18 years old or more\n* With Type 2 Diabetes\n* Treated with GLP 1 analog for more than 3 months\n* Signed consent\n* ASA between I and IV\n\nExclusion Criteria:\n\n* Insuline treatment\n* Gastro intestinal motility disorders\n* Past gastric surgery\n* Hiatal hernia\n* Recent trauma\n* Inability to be lay down for the exam\n* Inability to follow the instructions for the exam (language, dementia)\n* BMI \\> 40\n* Inability to stop smoking 12h before the measures",{"count":350,"type":22},38,"7 Days","Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach.\n\nThis is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days.\n\nTo recruit the necessary number of participants, approximately 1.5 years will be needed.\n\nThis project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project.\n\nThe project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and\u002For cereals and\u002For proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam.\n\nAt 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.",[29,354,355],"Regurgitation","Pulmonary Aspiration During Anaesthetic Induction",[357,358,31,359,360,361],"GLP-1 agonists","GLP-1 analog","Gastric ultrasound","Anesthesia","GUS","2026-03-27",{"date":333,"type":40},{"date":333,"type":22},{"date":112,"type":22},{"name":367,"class":85},"University Hospital, Geneva",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":180,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":48},"100631062","magnetic-compression-anastomosis-procedure-for-partial-jejunoileal-anastomosis-assessing-the-viability-of-an-innovative-metabolic-approach-100631062","NCT07495787","Magnetic Compression Anastomosis Procedure for Partial Jejunoileal Anastomosis: Assessing the Viability of an Innovative Metabolic Approach","Inclusion Criteria:\n\n* Subjects will be included in the study if they meet the following criteria:\n\n  1. Participant is willing and able to give informed consent for participation in the study.\n  2. Male or Female, aged ≥ 25 years to ≤ 65 years.\n  3. BMI greater than or equal to 25 and less than 50\n  4. Clinical diagnosis of T2DM by plasma glucose criteria, either the fasting plasma glucose (FPG) value or the 2-h plasma glucose (2-h PG) value during a 75-g oral glucose tolerance test (OGTT), or A1C criteria\n  5. Glycated Hemoglobin greater than or equal to 7.5% and less than 10.5% in at least one laboratory analysis conducted within the past 3 months, typically associated with a recommendation by patient's primary care physician and\u002For endocrinologist for intensification of treatment beyond oral medications\n  6. Currently taking oral combination therapy for T2DM\n  7. At least 12 months of experience with Diabetes Self-Management and Support\n\nExclusion Criteria:\n\n* 1\\. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months 2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 3. Current enrolment in another research study or previous participation within 30 days of enrolment 4. Current history of injected Glucagon Like Peptide 1 (GLP1) 5. American Society of Anesthesiologists (ASA) physical classification level of 4 or greater 6. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party-assistance, in the last year) 7. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies 8. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging 9. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum 10. History of small bowel surgery such as small bowel resection 11. Active H. pylori infection (prospective participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.) 12. History of chronic or acute pancreatitis 13. Known active hepatitis or active liver disease 14. Symptomatic gallstones or kidney stones or acute cholecystitis\n\nSubjects will be deemed ineligible to participate if they fulfill any of the following criteria:\n\n1. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months\n2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)\n3. Current enrolment in another research study or previous participation within 30 days of enrolment\n4. Current history of injected Glucagon Like Peptide 1 (GLP1)\n5. American Society of Anesthesiologists (ASA) physical classification level of 4 or greater\n6. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party-assistance, in the last year)\n7. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies\n8. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging\n9. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum\n10. History of small bowel surgery such as small bowel resection\n11. Active H. pylori infection (prospective participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.)\n12. History of chronic or acute pancreatitis\n13. Known active hepatitis or active liver disease\n14. Symptomatic gallstones or kidney stones or acute cholecystitis\n15. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia\n16. Use of anticoagulation therapy (such as warfarin) which cannot be discontinued for 7 days before and 14 days after the procedure\n17. Use of P2Y12 inhibitors (clopidogrel, pasugrel, ticagrelor) which cannot be discontinued for 14 days before and 14 days after the procedure (use of low-dose aspirin allowable)\n18. History of serious complications of T2DM including coronary artery disease, hypertension, peripheral vascular disease, diabetic retinopathy, and\u002For diabetes-related soft tissue infection\n19. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide)\n20. Receiving weight loss medications such as Meridia, Xenical, or over-the-counter weight loss medications\n21. Persistent anemia, defined as Hgb\\\u003C10 g dL-1\n22. Estimated Glomerular Filtration Rate (eGFR) or Modified of Diet in Renal Disease (MDRD) \\\u003C30 ml\u002Fmin\u002F1.73m2\n23. Active systemic infection\n24. Currently on anticoagulation therapy other than a low-dose aspirin regimen\n25. Chemotherapeutic cancer treatment within past 9 months, history of abdominal radiation, or active malignancy within the past 5 years\n26. Active illicit substance abuse or alcoholism\n27. Known sensitivity to possible medications used before, during, or after the Connect procedure, including but not limited to the following: sedative agents, general anesthetics, topical anesthetics, and opioid analgesics\n28. Any other serological markers likely to be associated with poor outcomes","65 Years",{"count":376,"type":22},5,[62],"English, Hindi and Gujarati",[29],[381],"Magnetic Compression Anastomosis","2026-03-24",{"date":362,"type":40},{"date":385,"type":40},"2025-04-22",{"date":387,"type":22},"2026-09-30",{"name":389,"class":47},"iIDEAS Group Holdings Limited",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":4},"100629217","monitoring-of-the-sympatheticvagal-balance-through-multiparametric-analysis-of-heart-rate-variability-hrv-100629217","NCT07471802","Monitoring of the Sympathetic\u002FVagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)","Monitoring of the Sympathetic\u002FVagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV) in Patients With Type 2 Diabetes Mellitus (Type 2 DM), With or Without Heart Failure and\u002For Chronic Kidney Disease, or Cardiomyopathy, With Heart Failure and\u002For Cardio-renal Syndrome, All Receiving Optimized Pharmacological Treatment, Including a Sodium-Glucose Co-transporter 2 Inhibitor (SGLT2i).","GLIFO-HRV","Inclusion Criteria:\n\n* Age over 18 years;\n* Signed informed consent;\n* in Sinus rhythm;\n* Patients for whom HOLTER ECG monitoring is clinically indicated, to early identify the possible onset or progression of diabetic autonomic neuropathy, or ischemic changes, or potentially arrhythmogenic electrophysiological alterations;\n* On optimized pharmacological treatment according to clinical practice, naïve to SGLT2 inhibitor therapy, prescribed according to the (1A) recommendations of the ESC 2023 guidelines.\n\nExclusion Criteria:\n\n* Patients with atrial fibrillation or other arrhythmic burden incompatible with accurate HRV analysis;\n* Pacemaker or ICD carriers;\n* Immunodeficient patients or patients at risk of developing infections.",{"count":232,"type":22},"The autonomic nervous system (ANS) plays a crucial role in cardiovascular regulation by modulating heart rate in response to endogenous and environmental stimuli. Heart rate variability (HRV) analysis has been widely used as a non-invasive tool to assess autonomic function and the balance between sympathetic and parasympathetic activity. Although the physiological interpretation of some HRV parameters remains debated-particularly the low-frequency (LF) spectral component as an index of sympathetic activation-HRV remains an important method for evaluating autonomic cardiovascular control.\n\nReduced HRV has been associated with adverse outcomes in several pathological conditions and physiologically declines with aging, mainly due to progressive neuronal loss at central and spinal levels. Among conditions characterized by autonomic dysfunction, cardiovascular autonomic neuropathy (CAN) represents a common complication of diabetes mellitus (DM) and metabolic syndrome. CAN, defined as impairment of autonomic control of the cardiovascular system, develops early in the disease course and is associated with increased mortality and a higher risk of cardiovascular and renal complications.\n\nSodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as glucose-lowering agents, have demonstrated significant cardiovascular and renal protective effects beyond glycemic control. Growing evidence suggests that these drugs exert sympathoinhibitory effects that may be beneficial not only in diabetic patients but also in conditions characterized by sympathetic overactivity. Preclinical and clinical studies have shown that SGLT2i influence autonomic regulation, including sympathetic control of renal function, with reported improvements in 24-hour blood pressure regulation and HRV parameters.\n\nLarge randomized trials have further confirmed the cardioprotective effects of SGLT2i therapy. Studies such as EMBODY, EMPEROR-Reduced, and EMPEROR-Preserved have demonstrated improvements in HRV indices and significant reductions in cardiovascular death and hospitalization for heart failure, irrespective of diabetic status.\n\nDespite these findings, the mechanisms underlying these benefits remain incompletely understood. While reduced sympathetic activity has been proposed as a key mechanism, emerging evidence suggests that SGLT2i may also enhance vagal modulation. Therefore, the present study aims to investigate, in a larger population, the effects of SGLT2i therapy on sympathovagal balance using both spectral HRV parameters and additional indices, including the parasympathetic nervous system index (PNSi), sympathetic nervous system index (SNSi), and the Baevsky Stress Index.",[29,401,402,403],"Heart Failure","Kidney Disease, Chronic","Cardiorenal Syndrome","2026-03-20",{"date":382,"type":40},{"date":407,"type":22},"2026-03-25",{"date":409,"type":22},"2031-09-01",{"name":411,"class":85},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":57,"sex":17,"minAge":181,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":48},"100630007","brain-blood-flow-and-sugar-transport-in-alzheimers-disease-with-and-without-diabetes---a-pilot-imaging-study-100630007","NCT07482072","Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study","Imaging Biomarkers in Alzheimer's Disease - an Exploratory PET Study","PETTAU","Inclusion Criteria:\n\n* suspected Alzheimer's disease\n* type 2 diabetes (group A)\n* able and willing to comply with study protocoil´´l\n\nExclusion Criteria:\n\n* type 2 diabetes (group B and C)\n* significant brain disease apart from dementia (group A and B)\n* significant vascular or neurological disease (group C)\n* active cancer treatment\n* history of alcohol or drug abuse\n* severe claustrophobia\n* pregnancy or breastfeeding","90 Years",{"count":422,"type":22},60,"Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier or more severely than others. Many people with Alzheimer's disease also have problems with blood flow and sugar handling in the brain, and these changes may play an important role in disease development. People with type 2 diabetes are at especially high risk of developing Alzheimer's disease and often experience a more severe disease course.\n\nThis pilot study aims to improve our understanding of how brain blood flow and sugar use are altered in Alzheimer's disease, and whether these changes differ in people with and without type 2 diabetes. We will study three groups: people with Alzheimer's disease without diabetes, people with Alzheimer's disease and type 2 diabetes, and healthy older individuals. By comparing these groups, we aim to identify early brain changes that may contribute to cognitive decline.\n\nParticipants will undergo advanced brain imaging using positron emission tomography (PET) scans. One scan uses a radioactive sugar tracer to measure how the brain takes up and uses glucose. Importantly, a new non-invasive method will also allow us to estimate how efficiently glucose is transported from the blood into the brain. This is a key process that may be impaired in Alzheimer's disease, but has previously required invasive procedures. The new approach avoids arterial cannulation, making the study safer and more comfortable for participants.\n\nA second PET scan will assess brain blood flow and blood vessel function, including how well the vessels can respond to increased demand. Participants will also complete cognitive tests to assess memory and thinking abilities.\n\nUltimately, this research may contribute to earlier diagnosis, better monitoring of disease progression, and development of new treatment strategies for Alzheimer's disease.",[425,29],"Alzheimer Dementia (AD)",[427,428,429,430,431],"neuroimaging","Alzheimer's disease","amyloid","glucose transport","glucose metabolism","2026-03-13",{"date":434,"type":40},"2026-03-19",{"date":436,"type":22},"2026-03",{"date":438,"type":22},"2026-12",{"name":440,"class":85},"Rigshospitalet, Denmark",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":449,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":48},"100629076","the-effect-of-sodium-glucose-co-trnasportert-type-2-inhibitors-on-arterial-stiffness-endothelial-glycocalyx-thickness-and-cardiac-deformation-after-acute-myocardial-infarction-100629076","NCT07469943","The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction","The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness , Left Atrial and Left Ventricular Deformation After Acute Myocardial Infarction","SGLT2i-MI-glyc","Inclusion Criteria:\n\n* STEMI participants with type 2 diabetes or LVEF\\\u003C40%\n\nExclusion Criteria:\n\n1. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m²\n2. Active malignancy\n3. Autoimmune or autoinflammatory disorders\n4. Severe hepatic impairment\n5. Pregnancy or breastfeeding",{"count":96,"type":22},"Acute myocardial infarction (MI) remains one of the leading causes of cardiovascular morbidity and mortality worldwide. It most commonly occurs due to acute coronary artery occlusion following rupture or erosion of an atherosclerotic plaque and subsequent thrombus formation. Despite significant advances in reperfusion strategies and guideline-directed pharmacological therapy, patients who survive MI remain at increased risk for adverse cardiovascular outcomes, including heart failure, recurrent myocardial infarction, stroke, and cardiovascular death. Therefore, additional therapeutic strategies that may improve vascular function, myocardial remodeling, and overall cardiovascular prognosis following MI are of considerable clinical interest.\n\nSodium-glucose cotransporter-2 (SGLT2) inhibitors have recently emerged as an important pharmacological class with significant cardiometabolic benefits. Large randomized clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of hospitalization for heart failure and cardiovascular mortality in patients with type 2 diabetes mellitus and in patients with heart failure irrespective of diabetic status. The cardioprotective effects of these agents appear to extend beyond glycemic control and include improvements in myocardial energetics, vascular function, inflammation, and oxidative stress. Emerging evidence suggests that SGLT2 inhibitors may also exert beneficial effects on vascular stiffness, endothelial function, and myocardial remodeling. However, data regarding their potential impact on arterial stiffness, endothelial glycocalyx integrity, and myocardial deformation parameters in the early post-myocardial infarction setting remain limited.\n\nThe primary aim of the present study is to investigate the effect of empagliflozin administration (10 mg daily) on arterial stiffness, endothelial glycocalyx thickness, and myocardial deformation indices of the left ventricle and left atrium during a 12-month follow-up period in patients presenting with ST-segment elevation myocardial infarction (STEMI).\n\nSecondary objectives include:\n\n1. evaluation of the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, recurrent myocardial infarction, and acute ischemic stroke;\n2. investigation of the association between the occurrence of MACE and vascular and myocardial functional parameters, including indices of arterial stiffness, endothelial glycocalyx integrity, and myocardial strain measurements; and\n3. assessment of oxidative stress burden through circulating biomarkers. This prospective observational study will include adult patients diagnosed with acute STEMI who are hospitalized in the Second University Cardiology Clinic of \"Attikon\" General Hospital. All participants will provide written informed consent prior to enrollment and will receive standard guideline-directed therapy for acute myocardial infarction according to the current European Society of Cardiology (ESC) guidelines.\n\nParticipants will be allocated into two groups. Group A will include patients receiving empagliflozin 10 mg once daily, initiated either at hospital discharge in patients with concomitant type 2 diabetes mellitus or in patients without diabetes who present with reduced left ventricular ejection fraction (LVEF \\\u003C40%). Group B will serve as the control group and will not receive empagliflozin therapy. The anticipated sample size of the study is 80 patients, with approximately 40 participants in each group.\n\nExclusion criteria include chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m², active malignancy, autoimmune or autoinflammatory disorders, severe hepatic impairment, and pregnancy or breastfeeding.\n\nParticipants will undergo detailed evaluation at baseline and at 3, 6, and 12 months. Arterial stiffness will be assessed through measurement of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP system, which represents the gold standard non-invasive method for evaluating large-artery stiffness. In addition, 24-hour pulse wave analysis will be performed using the Mobil-O-Graph device to obtain central hemodynamic parameters.\n\nEndothelial function will be evaluated through assessment of endothelial glycocalyx thickness in sublingual microvessels using Sidestream Dark Field (SDF) imaging with the GlycoCheck system. Glycocalyx integrity will be quantified by the Perfused Boundary Region (PBR) index, which reflects erythrocyte penetration into the glycocalyx layer and serves as a marker of endothelial barrier dysfunction.\n\nCardiac structure and function will be assessed using two-dimensional speckle-tracking echocardiography. Global longitudinal strain (GLS) of the left ventricle will be calculated using the standard 17-segment model from apical views, while left atrial strain will be measured to evaluate atrial reservoir and contractile function, providing sensitive markers of myocardial remodeling after infarction",[452,29],"Myocardial Infarction (MI)",[454,455,456,457],"arterial stiffness","sglt2i","myocardial deformation","endothelial glycocalyx","2026-03-10",{"date":432,"type":40},{"date":461,"type":40},"2026-01-09",{"date":463,"type":22},"2028-12-20",{"name":465,"class":85},"University of Athens",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":474,"targetDuration":476,"studyType":255,"phases":4,"briefSummary":477,"conditions":478,"keywords":481,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":48},"100628885","precision-medicine-and-neurodegenerative-diseases-advanced-systems-for-the-diagnosis-and-treatment-of-parkinsons-disease-and-alzheimers-disease-100628885","NCT07467460","Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.","NEUROTECHNO: Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.","NEUROTECHNO","Inclusion Criteria:\n\n* -Inclusion Criteria:\n* Inclusion criteria for PD patients. For the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli.\n\nPresence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset), one of which must be tremor or bradykinesia:\n\nAbsence of atypical symptoms such as: i) early postural instability, freezing episodes, cognitive decline, hallucinations, pathological involuntary movements, vertical gaze palsy; ii) confirmed causes of secondary parkinsonism (focal lesions, medications, toxic substances); Documented response to L-dopa or dopamine agonists (or lack of an adequate therapeutic trial with L-dopa or dopamine agonists).\n\n-Inclusion criteria forAD patients. For the University of Campania, patients will be selected at the Department of Advanced Medical and Surgical Sciences of the University of Campania \"L. Vanvitelli,\" located at Piazza Miraglia 2, Naples. The Department will establish a collaboration with the Alzheimer's day centers of ASL NA1 (Geriatric Facility \"Villa Walpole\" - Via Ponti Rossi, 118 - Naples, and Geriatric Facility \"Frullone\" - Via Comunale del Principe, 16\u002FA - Naples) to identify potential subjects for screening to verify the parameters required for recruitment. The Geriatrics and Internal Medicine Unit (UOC), AOU University of Campania, will also be involved.\n\nPatients with AD will be included following a diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011), supported by positive biomarkers for amyloidopathy (amyloid PET or cerebrospinal fluid amyloid assay).\n\nExclusion Criteria:\n\n* Pre-existing psychiatric disorders;\n* Neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neuromuscular disorders, epilepsy;\n* Diagnosis of dementia.",{"count":475,"type":22},500,"24 Months","In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the prevalence of age-related diseases. Among these, Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes (T2D) currently represent a major threat to human health. PD and AD are the most common neurodegenerative diseases in industrialized populations. In particular, AD accounts for 54% of all cases of dementia, with a prevalence of 4.4% among individuals over 65 years of age. PD has a prevalence of about 1% in people older than 60 years, reaching up to 4% in those over 80 years of age. AD and PD are highly disabling disorders with a slow but progressive course, caused by the degeneration and\u002For death of nerve cells. This results in impairments in the control of movement and balance, as in the case of PD, or in cognitive functioning, as in AD.\n\nTo date, neither effective treatments nor early diagnostic tools are available to address these conditions in the initial phase of neurodegeneration. Likewise, there are no tools capable of monitoring disease progression and improving patients' adaptation to therapy.\n\nMoreover, although the association between T2D and the risk of PD and\u002For AD has long been recognized, these conditions were historically considered unrelated. Recent evidence from clinical and epidemiological studies suggests the existence of shared pathophysiological mechanisms associated with insulin resistance and persistent inflammation in several metabolically relevant tissues, such as adipose tissue and the brain. However, the mechanisms that increase the risk of PD and\u002For AD in individuals with T2D remain poorly understood.\n\nThese data highlight how relevant these diseases are for the National Health System and demonstrate that they represent one of the most important priorities to be addressed, requiring substantial investments in both scientific research and early diagnostic strategies.\n\nTherefore, the present project proposal, which aims to develop new minimally invasive tools for the early prediction and monitoring of neurodegenerative diseases such as AD and PD, will help fill an important gap in the clinical and therapeutic management of these patients.",[479,480,29],"PARKINSON DISEASE (Disorder)","Alzheimer s Disease",[482,483,484],"Identification of genetic and metabolic profiles associated with neurodegenerative diseases","Identification of epigenetic profiles associated with neurodegenerative diseases","Integration and analysis of omics and neuroimaging data","2026-03-09",{"date":487,"type":40},"2026-03-12",{"date":489,"type":40},"2026-02-17",{"date":491,"type":22},"2028-09-30",{"name":493,"class":85},"Neuromed IRCCS",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":502,"maxAge":154,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":518},"100487953","phase-3-colchicine-and-non-enteric-coated-aspirin-in-the-cardiovascular-outcomes-trial-of-patients-with-type-2-diabetes-100487953","NCT05633810","COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes","COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (COLCOT-T2D)","COLCOT-T2D","Inclusion Criteria:\n\n1. Men and women aged 55 to 80 years\n2. Type 2 diabetes treated as per national guidelines\n3. No previous history of coronary artery disease-related clinical event\n4. And at least one of the following:\n\n   1. Duration of diabetes of 5 years or more,\n   2. HbA1c ≥ 8.0% or more in the last 2 years\n   3. Active cigarette smoking,\n   4. High hs-CRP (\\> 2.0 mg\u002FL),\n   5. High coronary calcium score (Agatston score \\>100),\n   6. High TG-levels (≥1.7 mmol\u002FL) despite lipid lowering therapy administered as per guidelines,\n   7. High LDL-C levels (≥3.5 mmol\u002FL) or high non-HDL-C levels (≥4.2 mmol\u002FL) despite lipid lowering therapy administered as per guidelines\n   8. High Apo-B (≥1.05 g\u002FL)\n   9. Reduced HDL-C (\\\u003C1.05 mmol\u002FL in men, \\\u003C1.3 mmol\u002FL in women),\n   10. Lp(a) \\>50 mg\u002FdL,\n   11. Peripheral artery disease with stenosis ≥50% or prior revascularization,\n   12. Cerebrovascular disease with stenosis ≥50% or prior revascularization,\n   13. Diabetic retinopathy or diabetic neuropathy,\n   14. Mild or moderate proteinuria (dipstick analysis) or micro-albuminuria\n5. Women of childbearing potential must have a negative urine pregnancy test at screening\u002Frandomization visit 1 and must agree to use an effective method of birth control throughout the study. Acceptable means of birth control include: oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner.\n\n   Women are considered not of childbearing potential if they either:\n   1. Have had a hysterectomy or tubal ligation prior to baseline visit or\n   2. Are postmenopausal defined as no menses for 12 months or a FSH level (if available) in the menopausal range.\n6. Patients with the capacity to provide informed consent.\n\nExclusion Criteria:\n\n1. Any prior history of myocardial infarction, angina, coronary revascularization, coronary stenosis \\>30%, stroke, transient ischemic attack, or known heart failure\n2. Known chronic renal insufficiency defined as an estimated glomerular filtration rate (eGFR), using the MDRD equation, of \\\u003C 35 mL\u002Fmin\u002F1.73m2\n3. History of cancer or lymphoproliferative disease within the last 3 years other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix and\u002For low-grade prostate cancer\n4. Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea\n5. Peptic ulcer diagnosed within the last 24 months or previous gastro-intestinal bleeding, except for mild hemorrhoidal bleeding more than 5 years ago which is permitted (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n6. Pre-existent progressive neuromuscular disease or known CPK level \\> 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing\n7. Any of the following known parameters as measured within the past 90 days, and determined to be non-transient through repeat testing:\n\n   1. hemoglobin \\\u003C 100 g\u002FL\n   2. 2\\. white blood cell count \\\u003C 3.0 X 10⁹\u002FL\n   3. platelet count \\\u003C110 X 10⁹\u002FL\n   4. ALT \\> 3 times the upper limit of normal (ULN)\n   5. total bilirubin \\> 2 times ULN (unless due to Gilbert syndrome, which is allowed)\n8. History of cirrhosis, chronic active hepatitis or severe hepatic disease\n9. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication\n10. History of clinically significant drug or alcohol abuse in the last year\n11. Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed, as well as replacement corticosteroids for adrenal insufficiency)\n12. Current chronic treatment with aspirin or another antiplatelet agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n13. Chronic treatment with an anticoagulant agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n14. Current use of colchicine for other indications (mainly chronic indications consisting of Familial Mediterranean Fever or gout); there is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment\n15. History of an allergic reaction or significant sensitivity to colchicine\n16. History of an allergic reaction or significant sensitivity to aspirin (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n17. Chronic treatment with an anti-inflammatory agent (for example, anti-TNF-alpha or nonsteroidal anti-inflammatory drug (NSAID))\n18. Use of an investigational chemical agent less than 30 days or 5 half-lives prior to the screening visit (whichever is longer)\n19. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.","55 Years",{"count":504,"type":22},10000,[276],"To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.",[29,508],"Cardiovascular Diseases",[510,511],"Diabetes (Type 2)","Heart Disease",{"date":458,"type":40},{"date":514,"type":40},"2022-12-21",{"date":244,"type":22},{"name":517,"class":85},"Montreal Heart Institute",39,{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":374,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":48},"100628924","impact-of-date-consumption-on-metabolic-control-and-oxidative-stress-in-patients-with-type-2-diabetes-100628924","NCT07467967","Impact of Date Consumption on Metabolic Control and Oxidative Stress in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Age 18-65 years\n* Type 2 diabetes diagnosed for at least one year\n* Well-controlled diabetes on oral antidiabetic drugs for at least 3 months, with a target baseline HbA1c \\\u003C 8%\n* Duration of diabetes \\\u003C 15 years\n* Patient available for an 8-week period\n* Written informed consent\n\nNon-inclusion Criteria:\n\n* Patients on insulin therapy\n* Oral antidiabetic treatment modified within the 3 months prior to inclusion\n* Diabetes with established microvascular or macrovascular complications\n* Severe intercurrent diseases (severe renal insufficiency, severe liver disease, cardiovascular history, neoplasia, inflammatory disease)\n* Pregnancy or breastfeeding\n* Known allergy or intolerance to dates\n* Dietary regimens incompatible with isocaloric substitution (e.g., strict ketogenic diet, prolonged fasting)\n* Inability to understand or comply with study instructions (cognitive impairment, language barrier without interpreter, major logistical constraints)\n\nExclusion Criteria:\n\n* Initiation of insulin therapy or major modification of antidiabetic treatment\n* Occurrence of pregnancy during the study\n* Development of a serious adverse event attributable to the intervention (e.g., persistent hyperglycemia, acute metabolic complications)\n* Patient refusal to continue the study or withdrawal of informed consent\n* Major non-adherence to the intervention (\\\u003C80% of planned intake or absence of isocaloric substitution)\n* Detection of a severe intercurrent condition requiring discontinuation of the intervention (e.g., heart failure decompensation, severe infection)\n* Loss to follow-up preventing the assessment of primary endpoints",{"count":526,"type":22},130,[62],"Summary\n\nDates, rich in simple sugars, fiber, and antioxidant polyphenols, have a variable glycemic index and conflicting reported effects on type 2 diabetes. Moderate consumption might raise glycemia if added to the usual diet, but could improve insulin sensitivity and oxidative balance if used as an isocaloric substitute.\n\nThis prospective, interventional, single-center study (Endocrinology Department., La Rabta Hospital, Tunis) aims to evaluate the effect of daily consumption of 3 Deglet Nour dates for 8 weeks on glycemic control and oxidative stress in 130 well-controlled type 2 diabetic patients.\n\nPrimary objectives:\n\nAssess changes in HbA1c, fasting glucose, and HOMA-IR. Measure variations in oxidative stress markers (MDA, SOD, TAC, pentosidine).\n\nSecondary objectives:\n\nMonitor changes in weight, BMI, waist circumference, and blood pressure. Assess tolerance, adherence, satisfaction, and adverse events.\n\nStudy design:\n\nBaseline and final visits (week 0 and week 8) with clinical, dietary, and laboratory assessments.\n\nIsocaloric substitution: 3 dates replace a carbohydrate portion (e.g., fruit or dessert).\n\nNo change in antidiabetic therapy or lifestyle allowed.\n\nEndpoints:\n\nPrimary: ΔHbA1c, Δfasting glucose, ΔHOMA-IR, and oxidative markers. Secondary: Anthropometrics, blood pressure, safety, adherence, lipid and metabolic parameters.\n\nExpected outcome: determine whether moderate, isocaloric date consumption is safe and potentially beneficial for metabolic control and oxidative balance in Tunisian patients with type 2 diabetes.",[29],[531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546],"Dates (Phoenix dactylifera)","Antioxidants","Polyphenols","Oxidative Stress","Diabetes Mellitus, Type 2","Blood Glucose","Glycated Hemoglobin A (HbA1c)","Insulin Resistance","Metabolic Control","Body Mass Index","Waist Circumference","Blood Pressure","Lipid Profile","Prospective Studies","Nutritional Status","Dietary Intervention","2026-03-08",{"date":487,"type":40},{"date":550,"type":22},"2026-07-15",{"date":552,"type":22},"2027-12-31",{"name":554,"class":85},"University Tunis El Manar",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":207,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":48},"100498912","phase-3-effect-of-a-healthy-food-voucher-on-blood-glucose-control-in-people-with-type-2-diabetes-or-prediabetes-100498912","NCT05776420","Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes","Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes: a Randomized Controlled Trial","VOUCH4DIABETES","Inclusion Criteria:\n\n* hemoglobin A1c 6.0 to 11.0\n* report food insecurity or financial insecurity\n\nExclusion Criteria:\n\n* live with a current study participant\n* life expectancy \\\u003C 6 months\n* multiple life-threatening allergies to common foods\n* require total parenteral nutrion\n* blood dyscrasia that interferes with hemoglobin A1c interpretation\n* hemoglobin A1c \\>11",{"count":564,"type":22},390,[276],"This randomized controlled trial (RCT) will determine if access to a voucher for healthy foods reduces blood sugar levels among people living on a low income who have type 2 diabetes or elevated blood sugar.",[29],"2026-02-05",{"date":570,"type":40},"2026-02-10",{"date":572,"type":40},"2023-03-21",{"date":574,"type":22},"2027-04-01",{"name":576,"class":85},"Unity Health Toronto",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":586,"briefSummary":587,"conditions":588,"keywords":591,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":86},"100621651","effects-of-lp-ldl-on-lipid-metabolism-glycemic-control-inflammatory-markers-and-cognitive-function-in-individuals-with-prediabetes-and-diabetes-mellitus-100621651","NCT07373392","Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus","Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus (Type 1 and Type 2)","Inclusion Criteria:\n\n* Adults ≥ 18 years\n* Prediabetes (FPG 100-125 mg\u002FdL or HbA1c 42-47 mmol\u002Fmol), or Type 1 or Type 2 diabetes\n* Elevated cholesterol or triglycerides (TC ≥200 mg\u002FdL, LDL 130-189 mg\u002FdL, or TG \\>150 mg\u002FdL)\n* Either no lipid-lowering medication or stable dose for ≥4 weeks\n* Able to swallow capsules and understand Danish\n* Willing to maintain lifestyle habits and provide stool and blood samples\n\nExclusion Criteria:\n\n* Antibiotic use in the past 3 months\n* Severe dyslipidemia (\\>500 mg\u002FdL triglycerides)\n* Significant liver, kidney, thyroid disease\n* Pregnancy or breastfeeding\n* GI surgery or chronic GI disease (IBD, IBS, Crohn's disease)\n* Long-term medications influencing lipid\u002Fglucose metabolism (except approved antidiabetic medications)\n* Participation in another trial within 3 months\n* Capsule intake \\\u003C80%",{"count":585,"type":22},210,[62],"This randomized, double-blind, placebo-controlled clinical trial investigates the effects of the probiotic LP-LDL® (Lactobacillus plantarum ECGC 13110402) on lipid metabolism, glycemic control, inflammatory biomarkers, and cognitive function in adults with prediabetes, type 1 diabetes, or type 2 diabetes who also exhibit elevated cholesterol or triglyceride levels.\n\nA total of 210 participants will be enrolled across three parallel sub-studies:\n\n* Type 1 diabetes (n = 76)\n* Type 2 diabetes (n = 54)\n* Prediabetes (n = 80)\n\nParticipants will be randomized 1:1 to receive LP-LDL® or matching placebo once daily for 12 weeks, followed by a 4-week washout period. Study assessments include fasting blood tests (lipids, glucose, HbA1c, liver enzymes, inflammatory markers), cognitive testing (ACE-III), blood pressure, anthropometry, and stool measurements (microbiome, bile acids, fecal fat).\n\nExploratory analyses include bile acid metabolism, microbiome profiling (16S rRNA), and gene expression of cholesterol transporters ABCG5\u002FABCG8.\n\nThe study aims to determine whether LP-LDL® can improve cardiometabolic profiles and cognitive outcomes in these populations, and to clarify the mechanistic pathways underlying metabolic dysfunction, inflammation, and gut-brain communication.",[589,29,590],"Diabete Type 1","Prediabetes",[590,592,593,594,595,596,597,598,599,600,601,602,603,604,605],"Type 1 Diabetes","Type 2 Diabetes","Dyslipidemia","Hypercholesterolemia","Metabolic dysfunction","Insulin resistance","Probiotics","LP-LDL","Lactobacillus plantarum","Lactobacillus plantarum ECGC 13110402","Dietary supplement","Microbiome modulation","LDL cholesterol","Cardiometabolic health","2026-01-27",{"date":608,"type":40},"2026-01-29",{"date":610,"type":22},"2026-01-25",{"date":612,"type":22},"2028-09-01",{"name":614,"class":85},"Aalborg University",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":624,"conditions":625,"keywords":626,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":48},"100605590","risk-factors-for-developing-peak-plantar-pressure-during-walking-in-the-diabetic-patients-100605590","NCT07164495","Risk Factors for Developing Peak Plantar Pressure During Walking in the Diabetic Patients","Investigation of the Risk Factors and Establishing a Prediction Model for Developing Peak Foot Pressure During Walking in the Diabetic Patients","Inclusion Criteria:\n\n* diagnosed with type 2 diabetes, at least for five years\n* aged older than 18 years\n* walk independently for at least 10 meter without any assistive device\n\nExclusion Criteria:\n\n* severe deformity in the foot or lower extremity\n* significant neuropathic or surgical diseases that affect normal walking function\n* cognitive dysfunction\n* active foot ulcer",{"count":623,"type":22},120,"The goal of this observational study is to investigate the clinically convenient dynamic and static measurement parameters to identify related risk factors of developing high peak plantar pressure during walking in the type-2 diabetic patients, and then establish a predictive model to estimate the likelihood of excessive plantar pressure.\n\nThe main question it aims to answer is:\n\nWhich clinical measurements may be used as the predictors that increased peak plantar pressure in the type-2 diabetic patients? Participants taking the examinations will understand their own clinally meaningful measurements related to their plantar pressure during walking. Further thorough analysis will be employed to develop a predictive model, aiming to provide potential improvement strategies for preventing diabetic foot ulcers in the future.",[29],[31,627,628],"Gait","Plantar Pressure","2026-01-26",{"date":631,"type":40},"2026-01-28",{"date":633,"type":40},"2024-10-01",{"date":635,"type":22},"2026-03-31",{"name":637,"class":85},"China Medical University Hospital",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":17,"minAge":207,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":650,"conditions":651,"keywords":652,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":656,"completionDateStruct":657,"leadSponsor":659,"locationsCount":48},"100621033","phase-4-evaluate-the-efficacy-and-safety-of-empagliflozin-or-glimepiride-combination-therapy-in-type-2-diabetes-mellitus-patients-100621033","NCT07365358","Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin","EMPAGO","Inclusion Criteria:\n\n* Over 19 years old\n* Type 2 diabetes mellitus\n* Patient who has been taking oral hypoglycemic agents for over 8 weeks\n* Agreement with written informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or secondary diabetes mellitus\n* Patients with complications of severe diabetes such as proliferative diabetic retinopathy\n* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption\n* Patients with abnormal laboratory test results according to the protocol\n* Continuous or non-continuous treatment with insulin for over 7 days within 12 weeks prior to screening\n* History of treatment with corticosteroids within 4 weeks prior to screening",{"count":647,"type":22},200,[649],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients",[29],[29,653],"Empagliflozin","2026-01-22",{"date":629,"type":40},{"date":436,"type":22},{"date":658,"type":22},"2027-08",{"name":660,"class":47},"Chong Kun Dang Pharmaceutical",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":57,"sex":17,"minAge":180,"maxAge":669,"enrollmentInfo":670,"targetDuration":4,"studyType":23,"phases":672,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":681,"leadSponsor":683,"locationsCount":4},"100619415","study-evaluating-the-safety-and-feasibility-of-endoscopic-duodenal-injections-of-autologous-mesenchymal-stem-cells-100619415","NCT07344324","Study Evaluating the Safety and Feasibility of Endoscopic Duodenal Injections of Autologous Mesenchymal Stem Cells","A Pilot Study Evaluating the Safety, Feasibility, and Therapeutic Potential of Endoscopic Duodenal Injection of Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Type 2 Diabetes Mellitus.","STEM-DM","Inclusion Criteria:\n\n* • Adults aged between 25-70 years\n\n  * Diagnosis of T2DM from at least 1 years\n  * HbA1c between 7.5% and 10%\n  * BMI between 25 and 35 kg\u002Fm²\n  * Fasting C-peptide ≥1 ng\u002Fml\n  * Stable antidiabetic regimen for ≥3 months (including insulin s.c.)\n  * Insulin resistance (HOMA-IR \\> 5)\n  * Healthy volunteers: BMI \\\u003C 25, age between 18-75 and no diagnosis of T2DM or insulin resistance (HOMA-IR\\\u003C2.5), with no significant acute or chronic medical conditions and not taking medications that could interfere with the esophagogastroduodenoscopy + biopsies\n\nExclusion Criteria:\n\n* Type 1 DM or secondary diabetes\n* Celiac disease\n* History of pancreatitis or GI surgery\n* Active infection or malignancies ongoing\n* Active gastro-duodenal ulcers\n* Duodenum not accessible endoscopically for previous surgery or other conditions\n* History of autoimmune disease\n* Active malignancy or recent cancer treatment\n* Use of certain medications (e.g., immunosuppressants, systemic corticosteroids)\n* Active Smoking (\\>5 sigarettes\u002Fdie)\n* Anticoagulant treatment not suspendable\n* Myocardial infarction during the past 6 months or\u002Fand heart failure class III or IV according to the New York Heart association's classification.\n* Drug or alcohol abuse\n* Continuous glucocorticoid or anti-inflammatory treatment\n* Uncontrolled thyroid disease.\n* Pregnancy, breastfeeding\n* Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study.\n* Liver cirrhosis of any Child-Phugh stage or MELD\\> 15\n* Chronic Severe Renal Insufficiency (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2 based on CKD-EPI equation)\n* Currently participating in other study, or previously participated in an experimental drugs trial within 30 days before or 5 half-life of the drug administered\n* Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator.","70 Years",{"count":671,"type":22},15,[62],"Type 2 Diabetes Mellitus (T2DM) pathogenesis increasingly involves \"diabetic duodenopathy,\" characterized by proximal intestinal immune and epithelial dysregulation. This study investigates the endoscopic delivery of adipose-derived mesenchymal stem cells (ADMSCs) into the duodenum and proximal jejunum as a disease-modifying therapy. By leveraging the paracrine immunomodulatory and regenerative effects of ADMSCs in close proximity to the pancreatico-enteroendocrine system, this targeted approach aims to restore insulin sensitivity and $\\\\beta$-cell function while minimizing systemic exposure. The clinical safety and feasibility of this novel delivery route remain to be established.",[29,675,676],"Insulin Resistant Diabetes (Mellitus)","Obesity","2026-01-07",{"date":679,"type":40},"2026-01-15",{"date":168,"type":22},{"date":682,"type":22},"2027-06-30",{"name":411,"class":85}]